Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A biorelevant in vitro release/permeation system for oral transmucosal dosage forms.

Delvadia PR, Barr WH, Karnes HT.

Int J Pharm. 2012 Jul 1;430(1-2):104-13. doi: 10.1016/j.ijpharm.2012.03.050. Epub 2012 Apr 3.

PMID:
22486954
2.

Evaluation of the effect of ammonia on nicotine pharmacokinetics using rapid arterial sampling.

McKinney DL, Gogova M, Davies BD, Ramakrishnan V, Fisher K, Carter WH, Karnes HT, Garnett WR, Iyer SS, Somani AA, Kobal G, Barr WH.

Nicotine Tob Res. 2012 May;14(5):586-95. doi: 10.1093/ntr/ntr257. Epub 2011 Dec 1.

PMID:
22140146
3.

Diazepam autoinjector intramuscular delivery system versus diazepam rectal gel: A pharmacokinetic comparison.

Garnett WR, Barr WH, Edinboro LE, Karnes HT, Mesa M, Wannarka GL.

Epilepsy Res. 2011 Jan;93(1):11-6. doi: 10.1016/j.eplepsyres.2010.10.001. Epub 2010 Dec 9.

PMID:
21145707
4.

Rapid automated blood sampling system for pharmacokinetics studies of cigarette smoking.

McKinney DL, Davies BD, Gogova M, Adams WM, Lewis W, Powell C, Iyer SS, Garnett WR, Karnes HT, Kobal G, Barr WH.

Nicotine Tob Res. 2010 Apr;12(4):319-25. doi: 10.1093/ntr/ntp190. Epub 2010 Feb 8.

PMID:
20142418
5.

A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.

Iyer SS, Barr WH, Karnes HT.

Int J Pharm. 2007 Aug 1;340(1-2):119-25. Epub 2007 Mar 30.

PMID:
17482777
6.

A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant.

Iyer SS, Barr WH, Dance ME, Coleman PR, Karnes HT.

Int J Pharm. 2007 Aug 1;340(1-2):104-18. Epub 2007 Mar 30.

PMID:
17482393
7.
8.
10.
11.

Transporters involved in apical and basolateral uptake of ceftibuten into Caco-2 cells.

Menon RM, Barr WH.

Biopharm Drug Dispos. 2002 Nov;23(8):317-26.

PMID:
12415572
12.

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP, Russell DA, Nesbitt JD, Powell JH, Thompson GA.

Pharm Res. 2001 Feb;18(2):166-70.

PMID:
11405286
13.

Oligonucleotide transport in rat and human intestine ussing chamber models.

Wu-Pong S, Livesay V, Dvorchik B, Barr WH.

Biopharm Drug Dispos. 1999 Dec;20(9):411-6.

PMID:
10951429
14.

Scientific and professional concerns regarding product interchange and subsequent monitoring of cyclosporine and other critical dose drugs.

Barr WH.

Transplant Proc. 1999 May;31(3):1645-8; discussion 1675-84. Review. No abstract available.

PMID:
10331033
15.
16.

Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

Cox KA, Dunn-Meynell K, Korfmacher WA, Broske L, Nomeir AA, Lin CC, Cayen MN, Barr WH.

Drug Discov Today. 1999 May;4(5):232-237.

PMID:
10322290
17.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH.

Am J Kidney Dis. 1999 Feb;33(2):389-97. Review.

PMID:
10023656
18.

Absorption of propranolol in humans following oral, jejunal, and ileal administration.

Buch A, Barr WH.

Pharm Res. 1998 Jun;15(6):953-7. No abstract available.

PMID:
9647365
20.

Evaluation of orally administered highly variable drugs and drug formulations.

Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, Dobrinska MR, Endrenyi L, Fairweather W, Gillespie W, Gonzalez MA, Hooper J, Jackson A, Lesko LJ, Midha KK, Noonan PK, Patnaik R, Williams RL.

Pharm Res. 1996 Nov;13(11):1590-4. Review. No abstract available.

PMID:
8956322
21.

Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: assessment using stereospecific and nonstereospecific assays.

Srinivas NR, Barr WH, Shyu WC, Mohandoss E, Chow S, Staggers J, Balan G, Belas FJ, Blair IA, Barbhaiya RH.

J Pharm Sci. 1996 Mar;85(3):299-303.

PMID:
8699333
22.

Pharmacokinetics of ceftibuten in children.

Barr WH, Affrime M, Lin CC, Batra V.

Pediatr Infect Dis J. 1995 Jul;14(7 Suppl):S93-101. Review.

PMID:
7567317
23.

Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers.

Hinderling PH, Tendolkar A, Dee CM, Barr WH, Seiberling M, Duerr H.

J Clin Pharmacol. 1995 Jul;35(7):721-9.

PMID:
7560253
24.

Pharmacokinetics of isepamicin.

Barr WH, Colucci R, Radwanski E, Zampaglione N, Cutler D, Lin CC, Elliott M, Affrime MB.

J Chemother. 1995 Jun;7 Suppl 2:53-61. Review.

PMID:
8622111
25.

A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.

Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH.

Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):641-6.

PMID:
7995006
26.

Analysis of multiple-dose bioequivalence studies.

Chinchilli VM, Esinhart JD, Barr WH.

J Biopharm Stat. 1994 Nov;4(3):423-35.

PMID:
7881454
27.

Differential absorption of amoxicillin from the human small and large intestine.

Barr WH, Zola EM, Candler EL, Hwang SM, Tendolkar AV, Shamburek R, Parker B, Hilty MD.

Clin Pharmacol Ther. 1994 Sep;56(3):279-85.

PMID:
7924123
28.

Workshop II report: scaleup of oral extended release dosage forms.

Skelly JP, Van Buskirk GA, Arbit HM, Amidon GL, Augsburger L, Barr WH, Berge S, Clevenger J, Dighe S, Fawzi M, et al.

J Pharm Sci Technol. 1994 Mar-Apr;48(2):95-101. Review. No abstract available.

PMID:
8032802
29.

Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers.

Chan KK, Buch A, Glazer RD, John VA, Barr WH.

Pharm Res. 1994 Mar;11(3):432-7.

PMID:
8008712
30.

Single-dose bioavailability of two extended-release lithium carbonate products.

Kirkwood CK, Wilson SK, Hayes PE, Barr WH, Sarkar MA, Ettigi PG.

Am J Hosp Pharm. 1994 Feb 15;51(4):486-9.

PMID:
8017413
31.

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al.

J Clin Pharmacol. 1994 Feb;34(2):111-9. No abstract available.

PMID:
8163710
32.

Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum.

Hsyu PH, Pritchard JF, Bozigian HP, Lloyd TL, Griffin RH, Shamburek R, Krishna G, Barr WH.

Pharm Res. 1994 Jan;11(1):156-9.

PMID:
8140047
33.

Scaleup of oral extended-release dosage forms.

Skelly JP, Van Buskirk GA, Arbit HM, Amidon GL, Augsburger L, Barr WH, Berge S, Clevenger J, Dighe S, Fawzi M, et al.

Pharm Res. 1993 Dec;10(12):1800-5. No abstract available.

PMID:
8302770
34.
35.

A correlation between digoxin plasma concentrations and systolic time intervals in hospitalized congestive heart failure patients.

Vemuri S, Barr WH, Propert DB.

Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):388-93.

PMID:
1446955
36.

The site of gastrointestinal absorption of gepirone in humans.

Tay LK, Dixon F Jr, Sostrin MB, Barr WH, Farmen RH, Pittman KA.

J Clin Pharmacol. 1992 Sep;32(9):827-32.

PMID:
1358923
37.

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al.

Pharm Res. 1992 Jun;9(6):826-33. No abstract available.

PMID:
1409369
38.

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al.

J Pharm Sci. 1992 Jun;81(6):605-10. No abstract available.

PMID:
1355792
39.

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, et al.

Clin Pharmacol Ther. 1992 Apr;51(4):465-73. No abstract available.

PMID:
1563216
40.

Cocaine inhalation in the rat: pharmacokinetics and cardiovascular response.

Boni JP, Barr WH, Martin BR.

J Pharmacol Exp Ther. 1991 Apr;257(1):307-15.

PMID:
2019993
41.

The pharmacokinetics of ceftibuten in humans.

Barr WH, Lin CC, Radwanski E, Lim J, Symchowicz S, Affrime M.

Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):93-100.

PMID:
2013216
42.

Report of the workshop on in vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms.

Skelley JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, Shah VP, Yacobi A.

J Pharm Sci. 1990 Sep;79(9):849-54. No abstract available.

PMID:
1980308
43.

Pharmacodynamic modeling of digoxin-induced bradycardia.

Vetticaden SJ, Barr WH, Allison TB.

J Pharmacokinet Biopharm. 1989 Feb;17(1):89-107.

PMID:
2715933
44.

Improved method for assaying digoxin in serum using high-performance liquid chromatography-radioimmunoassay.

Vetticaden SJ, Barr WH, Beightol LA.

J Chromatogr. 1986 Nov 28;383(1):187-93. No abstract available.

PMID:
3818836
45.

Digoxin absorption in a patient with short-bowel syndrome.

Vetticaden SJ, Lehman ME, Barnhart GR, Barr WH.

Clin Pharm. 1986 Jan;5(1):62-4. No abstract available.

PMID:
3948487
46.

Effect of ibuprofen on lithium plasma and red blood cell concentrations.

Kristoff CA, Hayes PE, Barr WH, Small RE, Townsend RJ, Ettigi PG.

Clin Pharm. 1986 Jan;5(1):51-5.

PMID:
3948485
47.

Warfarin absorption in a patient with short-bowel syndrome.

Lehman ME, Kolb KW, Barnhart GR, Wagman LD, Barr WH.

Clin Pharm. 1985 May-Jun;4(3):325-6. No abstract available.

PMID:
4006397
48.

The once-daily theophylline controversy.

Barr WH.

Pharmacotherapy. 1984 Jul-Aug;4(4):167-8. No abstract available.

PMID:
6483636
49.

Determination of quinidine and dihydroquinidine in plasma by high performance liquid chromatography.

Kline BJ, Turner VA, Barr WH.

Anal Chem. 1979 Mar;51(3):449-51. No abstract available.

PMID:
532974
50.

Dose-dependent bioavailability of tetracycline in man.

Adir J, Barr WH.

J Pharmacokinet Biopharm. 1978 Apr;6(2):99-110. No abstract available.

PMID:
671223

Supplemental Content

Support Center